Clinical trial · Observational
Imaging Markers of Subclinical Cardiotoxicity in Breast Cancer
NCT02666378CI-TRIAL-00081231completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This research study is evaluating the use of Cardiac Magnetic Resonance Imaging (CMR) as a method of detecting early signs of damage to the heart that can be associated with anthracycline-based chemotherapy for the treatment of breast cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cardiac Magnetic Resonance Imaging (CMR) | Other | — | UNRESOLVED |
| Echocardiogram (ECHO) | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- CMR/ECHO
- description
- Prior to starting chemotherapy treatment, the participant will undergo the following procedures: * Cardiac Magnetic Resonance Imaging (CMR) * Echocardiogram (ECHO) in patients with no clinically indicated scans * Each imaging procedure will be repeated at predetermined times during the protocol * Simple blood collection for plasma biomarker analysis
- interventionNames
- Other: Cardiac Magnetic Resonance Imaging (CMR)
- Other: Echocardiogram (ECHO)
Primary outcomes (1)
- measure
- Cardiotoxicity
- timeFrame
- 1 year after completion of treatment
- description
- Cardiotoxicity as measured by changes in left ventricular ejection fraction within one-year of completion of treatment
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age \> 18 years * Have histologic diagnosis of breast carcinoma * Scheduled to receive standard clinical therapy designed by their treating oncologist * Patients should receive anthracycline as part of the recommended treatment * Able to give informed consent. Exclusion Criteria: * Contraindication to contrast CMR including eGFR \<30 mls/min/1.73m2 * Uncontrolled serious concurrent illness * Pregnancy or breast feeding
References
Publications (0)
Data not yet available
No reference posted for this study.